Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Article

Sick Euthyroid Syndrome on Presentation of Patients With COVID-19: A Potential Marker for Disease Severity

Yair Schwarz, MD, MPH1, 2, *, Ruth Percik, MD1, 2, Bernice Oberman, MSc 3, Dana Yaffe, PhD 4, Eyal Zimlichman, MD, MSc 2, 5, Amir Tirosh, MD, PhD 1, 2

1 Dalia and David Arabov Endocrinology and Diabetes Research Center, Institute of Endocrinology, Sheba Medical Center, Tel Hashomer, Israel
2 Sackler Faculty of Medicine, Tel Aviv University, Israel
3 Gertner Institute for Epidemiology and Health Policy, Sheba Medical Center, Tel Hashomer, Israel
4 MDCClone, HaEnergia Street 77, Be’er Sheva, Israel
5 Central Management, Sheba Medical Center, Tel Hashomer, Israel

Objective: Precise risk stratification and triage of coronavirus disease 2019 (COVID-19) patients are essential in the setting of an overwhelming pandemic burden. Clinical observation has shown a somewhat high prevalence of sick euthyroid syndrome among patients with COVID-19. This study aimed to evaluate the predictive value of free triiodothyronine (FT3) at the clinical presentation of COVID-19 for disease severity and death.

Methods: This retrospective cohort study was based on electronic medical records. The study was conducted at Sheba Medical Centre, a tertiary hospital where several acute and chronic wards have been dedicated to the treatment of patients with COVID-19. The primary outcome measure was death during hospitalization; secondary outcomes included hospitalization in intensive care, mechanical ventilation, and length of hospitalization.

Results: Of a total of 577 polymerase chain reaction-positive patients with COVID-19 hospitalized between February 27 and July 30, 2020, 90 had at least 1 measurement of thyroid-stimulating hormone, free thyroxine, and FT3 within 3 days of presentation. After applying strict exclusion criteria, 54 patients were included in the study. Patients in the lowest tertile of FT3 had significantly higher rates of mortality (40%, 5.9%, and 5.9%, \( P = .008 \)), mechanical ventilation (45%, 29.4%, and 0.0%; \( P = .007 \)) and intensive care unit admission (55%, 29.4%, and 5.9%, \( P = .006 \)). In multivariate analyses adjusted for age, Charlson comorbidity index, creatinine, albumin, and white blood cell count, FT3 remained a significant independent predictor of death.

Conclusion: FT3 levels can serve as a prognostic tool for disease severity in the early presentation of COVID-19.

© 2021 AACE. Published by Elsevier Inc. All rights reserved.

Introduction

Precise stratification and triage of coronavirus disease 2019 (COVID-19) patients early during the course of hospitalization have become essential in the setting of emergency departments and intensive care units (ICUs) overwhelmed by the pandemic burden.1, 3, 4 Age and pre-existing conditions, including obesity, diabetes, cardiovascular disease, and hypertension (HTN), are associated with increased mortality.5-7 Additionally, laboratory markers, including D-dimer, ferritin, and lymphocyte count, have additional prognostic value.1 Clinical observations have revealed a relatively high prevalence (up to 64%) of sick euthyroid syndrome (SES) among patients with COVID-19, with some exhibiting a profound decrease in thyroid hormone levels,8 although the prognostic significance of this observation is currently unknown. SES is a physiologic adaptation to acute or chronic illness of the hypothalamic-pituitary-thyroid-(peripheral tissues) axis characterized by a decrease in thyroid hormone levels and thyroid-stimulating hormone (TSH).
despite absent intrinsic thyroid dysfunction at baseline.\(^5\) The available research on SES provides considerable knowledge on etiology, correlation with disease severity, and its prognostic value in a variety of acute and chronic states.\(^6\)–\(^14\) Specifically, free triiodothyronine (FT3) has been shown to be a robust predictor of ICU mortality. In a prospective trial involving 480 critically ill patients admitted to the ICU, FT3 levels served as an independent and powerful predictor of mortality.\(^1\) The course of SES includes a decline in serum triiodothyronine levels as early as 24 hours after disease onset, accompanied by a reciprocal increase in reverse T3 (RT3). Serum total thyroxine levels decline as the acute illness progresses\(^15\),\(^16\) whereas free thyroxine (FT4) hormone levels remain normal.\(^17\) The recovery phase is characterized by a gradual increase in serum TSH levels\(^16\) and may even be prolonged for months following clinical recovery. Of all the thyroid hormones, FT3 stands out as a marker of SES because it is the most dynamic hormone in the evolution of SES and is conventionally measurable, as opposed to RT3.\(^9\),\(^18\),\(^19\)

The COVID-19 pandemic burden requires accurate triage based on the early identification of individuals at risk of developing severe disease. The aim of this study was to prognostically evaluate thyroid hormone levels, specifically FT3, at COVID-19 presentation.

**Methods**

This retrospective was study conducted at Sheba Medical Centre, a tertiary academic hospital in Israel. During the 2020 COVID-19 pandemic, several acute and chronic wards, including internal medicine, intensive care, obstetrical, pediatric, psychiatric, and rehabilitation wards, were dedicated for the treatment of patients with COVID-19.

The study included patients aged \(\geq 18\) years with documented polymerase chain reaction (PCR)-positive COVID-19 infection. Exclusion criteria included underlying thyroid disease based on diagnosis or chronic medications; treatment with drugs that might interfere with thyroid function, including amiodarone, interferon, and glucocorticoids (other than chronic treatment with a low-dose glucocorticoid); exposure to an iodine-containing contrast medium before thyroid hormone measurement; and admission for rehabilitation after initial recovery from an acute COVID-19 infection. Medical records of PCR-positive patients with COVID-19 hospitalized between February 27 and July 30, 2020, were retrieved and searched using MDClone (mdclone.com), a query tool that provides a wide range of patient data during a predefined time frame around an index event,\(^20\) and electronic medical records (Chameleon, version 5.12.2.43395, Elad Health). The index event was defined as hospitalization with a COVID-19 diagnosis in patients aged \(\geq 18\) years old.

Patient data queried included demographic data, medical history, laboratory parameters related to the index event, hospitalization, transfer between wards, mechanical ventilation, discharge, and death. Thyroid function tests were performed in the hospital’s core laboratory using immunoassays (UniCel Dxl 800 Immunoassay System, Beckman Coulter Diagnostics; normal reference ranges: TSH 0.4-4.0 mIU/L, FT4 7-16 pmol/L, and FT3 3.3-7.2 pmol/L; interassay coefficients of variation \(\leq 5\%\), 8.8%, and 8%, respectively; and intra-assay coefficients of variation \(\leq 2\%\), 4.4%, and 6.6%, respectively).

The Charlson score was calculated for each patient. The Charlson comorbidity index, developed by Charlson\(^21\) in 1987, is based on 19 conditions found to significantly influence survival and is a reflection of the number and severity of the comorbidities that a patient has. The comorbidities present in a patient are weighted and summed to give the final score, taking into account the person’s age.

The primary outcome of the study was death during hospitalization: secondary outcomes included hospitalization in the ICU, mechanical ventilation, and length of hospitalization. Demographic, clinical, and laboratory variables were compared between FT3 tertiles and between the groups of survivors and nonsurvivors. Continuous variables that were normally distributed were compared between groups using t tests or analysis of variance as indicated, adjusting, if necessary, for inequality of variances. Continuous

---

**Fig. 1.** Study flowchart. FT3 – free triiodothyronine.
variables that were not normally distributed were compared using the Kruskal-Wallis rank-sum test. Categorical variables were compared using $\chi^2$ or Fisher exact test according to sample size.

Univariate logistic regression was performed to determine risk factors for mortality. Significant variables resulting from the univariate logistic regression were entered into multivariate logistic regression models. Models were compared using a pseudo $R^2$. The best cutoff point was determined using the Youden index. A Kaplan-Meier analysis assessed the probability of survival in the different FT3 groups, which were compared using the log-rank test.

All analyses were performed using R. The study was approved by the Sheba Medical Center Institutional Review Board.

**Results**

**Patients**

A total of 577 adult patients were diagnosed with COVID-19 and hospitalized in dedicated wards between February 27 and July 30, 2020 (Fig. 1). Patients without an initial FT3 measurement ($n = 395$), with prior thyroid disease ($n = 17$), or undergoing hospitalization for rehabilitation ($n = 11$) were excluded. Of the remaining
119 individuals, 47 patients were excluded for not having an FT3 measurement within 3 days of presentation (defined as the time window for COVID-19 presentation). An additional 16 patients who had received treatment with glucocorticoids before their first FT3 measurement (other than 1 subject on 5-mg prednisone for renal transplantation) were excluded, and 2 patients who had been exposed to iodinated contrast material prior to their thyroid hormone measurements were also excluded from the analysis. None of the remaining patients in the cohort were treated with amiodarone.

The remaining 54 patients included in the statistical analysis were divided into tertiles according to their FT3 levels (2.4-4.0, 4.1-4.8, and 4.9-7.4 pmol/L, respectively). Patients in the lowest tertile included patients with an FT3 value below the reference range or in the lower part of the reference range; this group of patients included those with SES. Demographic and clinical characteristics were compared between the FT3 tertiles and are shown in Table 1.

Clinical and Laboratory Characteristics According to FT3 Stratification

Participants in the lowest FT3 tertile were significantly older compared with the higher tertiles (68.7, 56.7, and 48.9 years, for the first, second, and third tertile, respectively; \( P = .006 \)), had a higher Charlson index score (5.0, 2.47, and 1.65, respectively; \( P < .001 \)), and a higher prevalence of diabetes mellitus (55%, 23.5%, and 17.6%, respectively; \( P = .033 \)). No significant differences were found with respect to body mass index, sex, HTN, ischemic heart disease, congestive heart failure, autoimmune disease, or diagnosis of cognitive decline. Patients in the lowest FT3 tertile had significantly lower mean room air oxygen saturation on presentation (81%, 92.7%, and 93.7%, respectively; \( P = .006 \)), and only patients in the lowest tertile required mechanical ventilation in the emergency department (5 patients vs 0 in both the higher tertiles; \( P = .009 \), data not shown). Patients in the lowest tertile had a higher creatinine level on presentation (1.3, 0.9, and 0.67 mg/dL, respectively;
a higher C-reactive protein level (154.8, 80.7, and 31.2 mg/L, respectively; \( P < .001 \)), a lower mean lymphocyte count (0.78, 1.05, and 1.36 K/μL, respectively; \( P = .005 \)), and a lower albumin level (3.23, 3.64, and 3.79 g/dL, respectively; \( P = .023 \)). Other laboratory markers for severe disease were also significantly different between the groups, including LDH (492.8, 352.4, and 289.9 IU/L, respectively; \( P = .01 \)), ferritin (921.9, 647.6, and 289.8 ng/mL, respectively; \( P = .002 \)), and troponin (109.7, 14.0, and 39.1 ng/L, respectively; \( P = .032 \)). D-dimer was not significantly different between the tertiles. No significant differences in TSH or FT4 at presentation with COVID-19 were found between the groups, but patients in the lowest FT3 tertile at presentation with COVID-19 reached a significantly lower TSH and FT4 nadir during the course of the disease (TSH: 1.3, 1.6, and 2.8 mIU/L, respectively; \( P = .039 \) and FT4: 9.2, 11.1, and 12.6 pmol/L, respectively; \( P = .011 \)).

**Primary and Secondary Outcomes**

Patients in the lowest FT3 tertile had a significantly higher mortality rate (40%, 5.9%, and 5.9% in the first, second, and third tertiles, respectively; \( P = .008 \)), more mechanical ventilation (45%, 29.4%, and 0.0%, respectively; \( P = .007 \)), and ICU hospitalization (55%, 29.4%, and 5.9%, respectively; \( P = .006 \)). The average length of hospitalization was not significantly different between the groups. A Kaplan-Meier 90-day survival analysis between the tertiles (Fig. 2) demonstrated the significant survival disadvantage of the lowest FT3 tertile (log-rank \( P = .032 \)). Study outcomes are shown in Table 1 and Figure 3. A full comparison of survivors with non-survivors is presented in Table 2.

**Comparison of Survivors with Nonsurvivors**

Of the 54 patients in our cohort, there were 10 deaths, of which 8 were in the lowest tertile of FT3. These patients had an average FT3 on presentation, which was significantly lower than that of the survivors (3.45 vs 4.65 pmol/L; \( P < .001 \)). Patients who died were significantly older (74.9 vs 55.0 years; \( P = .03 \)) and had a higher Charlson index score (6.1 vs 2.48; \( P < .001 \)). There were no significant differences regarding body mass index and pre-existing comorbidities. Heart rate, mean room air saturation, respiratory rate, temperature, and blood pressure were not significantly different at presentation. Laboratory markers that were significantly different between nonsurvivors and survivors included the white blood cell (WBC) count (14.6 vs 7.5 K/μL; \( P = .001 \)), absolute neutrophil count (12.8 vs 5.5 K/μL; \( P = .001 \)), and albumin (2.79 vs 3.70 g/dL; \( P < .001 \)). Several markers for severe disease, including creatinine, LDH, and D-dimer, were borderline significant between the 2 groups. In a univariate analysis, baseline characteristics that were significantly associated with a higher risk of death included older age (odds ratio [OR] 1.07, 95% CI: 1.02-1.12) and a higher Charlson index (OR 1.7, 95% CI: 1.22-2.37). When analyzing the association of thyroid hormones at presentation and death, lower FT3 levels were significantly associated with death, but neither TSH or FT4 levels were significant for mortality (OR for FT3: 0.17, 95% CI: 0.05-0.54). Other laboratory markers significantly associated with death were low albumin (OR 0.02, 95% CI: 0.00-0.25), low WBC count (OR 1.34, 95% CI: 1.11-1.63), and low neutrophil count (OR 1.37, 95% CI: 1.12-1.67). The ORs for FT3 and albumin were low because, unlike other variables associated with death, a higher FT3
and higher albumin levels are associated with a decreased risk of death.

In multivariate analyses adjusted for age, Charlson index, WBC count, neutrophil count, and albumin as separate covariates, FT3 remained a statistically significant predictor of death. However, after adjustment for FT3, age, HTN, and creatinine were no longer significant ($P = .06$, .12, and .78, respectively), while low albumin, Charlson index score, WBC count, and neutrophil count retained their significance as predictors of mortality ($P = .01$, .035, .012, and .013, respectively).

FT3 alone (in a univariate analysis) was found to be a significant predictor of mortality ($R^2 = 0.38$), and the addition of 1 of the other

| Table 2 | Comparison of Survivors to Nonsurvivors |
|---------|----------------------------------------|
| Variable | Survivors (n = 44) | Nonsurvivors (n = 10) | $P$ value | Univariate OR (± CI) | $P$ value<sup>a</sup> | Multivariate ORs (± CI)<sup>b</sup> | $P$ value<sup>c</sup> | $R^2$ |
| Age, mean (SD) | 55.05 (18.43) | 74.93 (15.36) | .003 | 1.07 (1.02, 1.12) | .007 | 1.06 (1.00,1.12) | .06 | 0.47 |
| Male (%) | 31 (70.5) | 6 (60.0) | .791 | ... | ... | ... | ... | ... |
| Female (%) | 13 (29.5) | 4 (40.0) | ... | ... | ... | ... | ... | ... |
| BMI, mean (SD) | 26.36 (4.87) | 26.84 (4.61) | .821 | ... | ... | ... | ... | ... |
| Medical background | | | | | | | | |
| DM (%) | 14 (31.8) | 4 (40.0) | .901 | ... | ... | ... | ... | ... |
| HTN (%) | 14 (31.8) | 7 (70.0) | .061 | 5.0 (1.12, 22.27) | .035 | 3.81 (0.69, 21.2) | .12 | 0.43 |
| CVA (%) | 5 (11.4) | 3 (30.0) | .315 | ... | ... | ... | ... | ... |
| IHD (%) | 2 (4.5) | 3 (30.0) | .057 | ... | ... | ... | ... | ... |
| CHF (%) | 1 (2.3) | 2 (20.0) | .15 | ... | ... | ... | ... | ... |
| Charlson index, mean (SD) | 2.48 (2.45) | 6.10 (2.13) | <.001 | 1.7 (1.22, 2.37) | .0017 | 1.48 (1.03, 2.14) | .035 | 0.49 |
| Thyroid hormones | | | | | | | | |
| TSH (mIU/L) | 2.65 (2.65) | 3.37 (4.78) | .52 | 1.07 (0.87, 1.31) | .51 | ... | ... | ... |
| FT4 (pmol/L) | 13.14 (4.11) | 13.49 (3.53) | .5 | 1.02 (0.87, 1.21) | .8 | ... | ... | ... |
| FT3 (pmol/L) | 4.65 (0.93) | 3.45 (0.77) | <.001 | 0.17 (0.05, 0.54) | .003 | ... | ... | ... |
| Laboratory results | | | | | | | | |
| Hb (g/dL) | 13.18 (2.23) | 11.87 (2.27) | .007 | 0.78 (0.58,1.06) | .11 | ... | ... | ... |
| WBC (K/µL) | 7.50 (3.34) | 14.66 (7.63) | .001 | 1.34 (1.11, 1.63) | .0026 | 1.28 (1.05, 1.56) | .013 | 0.58 |
| Neutrophils (K/µL) | 5.59 (2.90) | 12.86 (8.21) | .001 | 1.37 (1.12, 1.67) | .0024 | 1.13 (1.05, 1.61) | .015 | 0.58 |
| Lymphocytes (K/µ) | 1.09 (0.60) | 0.84 (0.35) | .3 | 0.39 (0.09, 1.7) | .21 | ... | ... | ... |
| Albumin (g/dL) | 3.70 (0.55) | 2.79 (0.59) | <.001 | 0.02 (0.00, 0.25) | .003 | 0.01 (0.00, 0.3) | .01 | 0.67 |
| Cr (mg/dL) | 0.88 (0.42) | 1.40 (0.99) | .08 | 3.28 (1.09, 9.84) | .034 | 1.2 (0.33, 4.33) | .78 | 0.38 |
| LDH (IU/L) | 357.79 (182.22) | 489.90 (229.62) | .06 | 1.0 (0.00, 1.01) | .07 | ... | ... | ... |
| D-dimer (ng/mL) | 4330.38 (12521.36) | 11474.00 (19677.18) | .07 | 1.0 (0.99, 1.00) | .23 | ... | ... | ... |
| Ferritin (ng/mL) | 617.44 (651.16) | 521.40 (571.27) | .95 | 0.99 (0.99, 1.00) | .71 | ... | ... | ... |
| Troponin-I HS (ng/L) | 17.26 (17.17) | 213.45 (329.72) | <.001 | 1.05 (1.01, 1.10) | .02 | ... | ... | ... |
| CRP (mg/L) | 82.16 (88.61) | 143.30 (98.06) | .053 | 1.01 (0.99, 1.01) | .07 | ... | ... | ... |
| AST (IU/L) | 52.36 (36.11) | 84.1 (88.25) | .69 | 1.01 (0.998, 1.02) | .1 | ... | ... | ... |
| ALT (IU/L) | 35.2 (20.93) | 53.6 (61.24) | .8 | ... | ... | ... | ... | ... |
| ED clinical parameters on presentation, mean (SD) | | | | | | | | |
| Oxygen room air saturation (%) | 88.31 (14.40) | 85.90 (13.07) | .47 | ... | ... | ... | ... | ... |
| HR (bpm) | 90.15 (17.48) | 95.50 (26.12) | .46 | ... | ... | ... | ... | ... |
| RR (respirations/min) | 23.84 (10.26) | 27.33 (8.19) | .34 | ... | ... | ... | ... | ... |
| Temperature (°C) | 37.73 (0.80) | 37.53 (0.67) | .5 | ... | ... | ... | ... | ... |
| SBP (mm Hg) | 134.37 (18.35) | 138.70 (24.27) | .54 | ... | ... | ... | ... | ... |
| DBP (mm Hg) | 77.74 (10.49) | 82.30 (8.90) | .22 | ... | ... | ... | ... | ... |

Abbreviations: ALT = alanine transaminase; AST = aspartate aminotransferase; BMI = body mass index; bpm = beats/min; CHF = congestive heart failure; Cr = creatinine; CRP = c-reactive protein; CVA = cerebrovascular accident; DBP = diastolic blood pressure; DM = Diabetes mellitus; FT3 = free triiodothyronine; FT4 = free thyroxine; Hb = hemoglobin; HR = heart rate; HS = high sensitivity; HTN = Hypertension; IHD = ischemic heart disease; LDH = lactate dehydrogenase; RR = respiratory rate; SBP = systolic blood pressure; TSH = thyroid stimulating hormone; WBC = white blood cell.

<sup>a</sup> $P$ value for univariate model.
<sup>b</sup> In the Multivariate OR (CI) column, the first OR (CI) is for the covariate and the second is for FT3
<sup>c</sup> $P$ values for multivariate model (with FT3). The $P$ value for FT3 is the second one for each model.
<sup>d</sup> Nagelkerke R for Multivariate model (with FT3). R2 for a model with FT3 alone is 0.38.
covariates in a model with FT3 strongly increased joint predictive ability (Table 2). These other covariates included age \((R^2 = 0.47)\), Charlson index \((R^2 = 0.49)\), WBC count \((R^2 = 0.58)\), and albumin levels \((R^2 = 0.67)\).

An ROC curve for the association between FT3 levels and death is shown in Figure 4. With a cutoff value of 4.15 pmol/L, the area under the curve \((AUC) = 0.843\) (95% CI: 0.705-0.981), the sensitivity was 90%, and the specificity was 70%. When compared with other variables that were found to be significantly associated with death, FT3 was superior to age and WBC count \((AUC = 0.79 and 0.83)\), respectively and inferior to albumin levels and Charlson index score \((AUC = 0.89 and 0.86)\), respectively.

**Comparison Between the Study Cohort and the General Population of Patients with COVID-19**

The study cohort was similar to the general population of patients hospitalized with COVID-19 with respect to age, sex, and medical history, with the exception of diabetes \((33.3\% vs 19.2\%; \ P = .027)\), but differed in laboratory markers for severe disease. These markers included the WBC count \((8.85 vs 7.93 \, K/\mu L; \ P < .001)\) and the levels of albumin \((3.54 vs 3.8 \, g/dL; \ P = .002)\), LDH \((382.72 vs 313.4 \, IU/L; \ P = .018)\), and troponin \((62.1 vs 55.2 \, ng/L; \ P < .001)\). As far as study outcomes were concerned, the study cohort had a significantly higher mortality rate \((18.5\% vs 3.5\%; \ P > .001)\), use of mechanical ventilation \((25.9\% vs 0.8\%; \ P > .001)\), ICU admission \((31.5\% vs 3.5\%; \ P < .001)\), and length of hospitalization \((26.2 vs 7.4 \, days; \ P < .001)\). A detailed comparison is shown in Table 3.

**Discussion**

Clinical observations have revealed a relatively high prevalence of SES among patients with COVID-19. These observations have raised the question of whether FT3 levels represent an integrative indicator of disease severity and a patient’s reserve early in the course of COVID-19 disease. We analyzed a cohort of 54 PCR-confirmed patients with COVID-19 who had a full thyroid function profile upon disease presentation. Patients with a low FT3 (in the lowest tertile of FT3 values) had a markedly higher disease severity and increased mortality (40% mortality rate) compared with patients with a higher FT3 (5% mortality rate in the higher tertiles). Low FT3 at presentation remained a robust predictor of mortality in multivariate analyses that included all other significant predictors: age, Charlson index, albumin level, WBC count, and neutrophil count. The FT3 ROC curve proved that FT3 was an excellent predictor of mortality \((AUC = 0.84)\), superior to age \((AUC = 0.79)\), and only slightly inferior to albumin levels \((AUC = 0.89)\) and the Charlson index \((AUC = 0.86)\).

**Table 3**

| Variable | Study cohort \((n = 54)\) | Hospitalized patients not in study cohort* \((n = 395)\) | \(P\) value |
|----------|----------------------------|------------------------------------------------|-----------|
| Age (mean (SD)) | 58.73 (19.40) | 57.29 (18.73) | .64 |
| Gender (%) | | | |
| Male | 37 (68.5) | 228 (57.7) | .172 |
| Female | 17 (31.5) | 167 (42.3) | ... |
| BMI, mean (SD) | 26.43 (4.78) | 27.41 (5.32) | .36 |
| Medical background | | | |
| DM (%) | 18 (33.3) | 76 (19.2) | .027 |
| HTN (%) | 21 (38.9) | 135 (34.2) | .596 |
| CVA (%) | 8 (14.8) | 30 (7.6) | .13 |
| IHD (%) | 5 (9.3) | 30 (7.6) | .59 |
| CHF (%) | 3 (5.6) | 19 (4.8) | .74 |
| PVD (%) | 1 (1.9) | 13 (3.3) | 1 |
| Autoimmune disease (%) | 2 (3.7) | 23 (5.8) | .76 |
| Cognitive decline (%) | 10 (18.5) | 37 (9.4) | .07 |
| Charlson index, mean (SD) | 3.15 (2.77) | 2.66 (2.67) | .19 |
| Laboratory tests, mean (SD) | | | |
| Hb (g/dL) | 12.94 (2.28) | 13.25 (1.88) | .52 |
| WBC (K/\mu L) | 8.85 (5.20) | 7.93 (26.73) | <.001 |
| Neutrophils (K/\mu L) | 6.94 (5.14) | 4.69 (3.08) | <.001 |
| Lymphocytes (K/\mu L) | 1.05 (0.57) | 1.19 (0.64) | .11 |
| PLT (K/\mu L) | 229.46 (116.47) | 194.95 (77.99) | .026 |
| Albumin (g/dL) | 3.54 (0.66) | 3.80 (0.51) | .002 |
| Cr (mg/dL) | 0.98 (0.59) | 0.90 (0.48) | .97 |
| AST (IU/L) | 58.24 (30.35) | 40.67 (28.42) | .003 |
| ALT (IU/L) | 38.61 (32.32) | 30.80 (26.57) | .02 |
| LDH (IU/L) | 382.72 (196.64) | 313.41 (128.85) | .018 |
| D-dimer (ng/mL) | 5691.07 (14154.82) | 1741.45 (5117.51) | .072 |
| Ferritin (ng/mL) | 601.80 (633.44) | 485.06 (600.04) | .5 |
| Troponin-I HS (ng/L) | 62.1 (172.03) | 55.24 (3427.82) | <.001 |
| CRP (mg/mL) | 93.69 (92.68) | 97.63 (92.68) | .19 |
| Study outcomes | | | |
| Death cases (%) | 10 (18.5) | 14 (3.5) | <.001 |
| Mechanical ventilation (%) | 14 (25.9) | 3 (0.8) | <.001 |
| ICU (%) | 17 (31.5) | 14 (3.5) | <.001 |
| LOS (d), mean (SD) | 26.21 (31.67) | 7.41 (9.21) | <.001 |

Abbreviations: ALT = alanine transaminase; AST = aspartate aminotransferase; BMI = body mass index; CHF = congestive heart failure; Cr = creatinine; CRP = c-reactive protein; CVA = cerebrovascular accident; DM = diabetes mellitus; Hb = hemoglobin; HTN = hypertension; ICU = intensive care unit; IHD = ischemic heart disease; LDH = lactate dehydrogenase; LOS = length of stay; PLT = platelets; PVD = peripheral vascular disease.

* Excluded patients who were excluded from the study and study cohort.

Fig. 4. ROC curve of association between FT3 levels and death, \(AUC = 0.84\). FT3 = free triiodothyronine; ROC = receiver-operating curve.
and TNF-α are more feasible biomarkers for COVID-19 risk stratification. Given the scarce availability of these methods in most medical centers and the availability of FT3 immunoassays, the latter is a satisfactory and signifcant increase in cytokines. Moreover, the rise in cortisol in the setting of acute infection may also exert a suppressive effect on TSH secretion, FT4 to FT3 conversion, and an increase in the conversion of T3 to T4. Low FT3 is likely to be an integrative marker for the host response to COVID-19 infection.

This study has several limitations. Due to the retrospective data collection, thyroid function tests were unavailable for all patients on admission. This might reflect diverse policies of laboratory assessment in different wards or the decision of medical staff to perform a more thorough initial laboratory work-up when assessing the patient. The study population is relatively small due to the meticulous cohort selection performed to evaluate FT3 as a predictor of mortality early in the course of hospitalization and without potential confounders, such as glucocorticoid treatment, which is very common among these patients. This stringent selection method limited the cohort size but was necessary for the clarity and signifcance of the results. We measured FT3 by a conventional automated clinical method rather than by equilibrium dialysis, which could overcome potential interference in the laboratory assay due to alterations in thyroid hormone-binding capacity. Given the scarce availability of these methods in most medical centers and the availability of FT3 immunoassays, the latter is a more feasible biomarker for COVID-19 risk stratification. In conclusion, our fi ndings suggest that FT3 provides a robust prognostic value that can serve as a valuable stratification tool for newly diagnosed patients with COVID-19.

Disclosure

The authors have no multiplicity in interest to declare.

Author Contributions

Y.S. and R.P. are co-primary authors.

References

1. Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020;95:304–307.
2. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091.
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242.
4. Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19: a retrospective study. Thyroid. 2020;31(1):8–11.
5. Moura Neto A, Zantut-Wittmann DE. Abnormalities of thyroid hormone metabolism during systemic illness: the low T3 syndrome in different clinical settings. Int J Endocrinol. 2016. https://doi.org/10.1155/2016/157583.
6. Wang F, Pan W, Wang H, Wang S, Pan S, Ge. J. Relationship between thyroid function and ICU mortality: a prospective observation study. Crit Care. 2012;16(6):R11.
7. Gutsch M, Kumar S, Gupta KK. Prognostic value of thyroid profile in critical care patients. Indian J Endocrinol Metab. 2018;22(3):387.
8. Bunevcicic A, Deluva V, Tamasauskas S, Tamasauskas A, Laws ER, Bunevicus R. Low triiodothyronine syndrome as a predictor of poor outcomes in patients undergoing brain tumor surgery: a pilot study. J Neurolingu. 2013;11(6):1279–1287.
9. Gangemi EN, Carino F, Berchella P, et al. Low triiodothyronine serum levels as a predictor of poor prognosis in burn patients. Burns. 2008;34(6):817–824.
10. Pavliou HN, Kliridis PA, Goritsas CP, Vasilakos PJ. Euthyroid sick syndrome in acute ischemic syndromes. Angiology. 2002;53(6):699–707.
11. Ozcan KS, Osmanov D, Toprak E, et al. Euthyroid sick syndrome is associated with poor prognosis in patients with ST segment elevation myocardial infarction undergoing primary percutaneous intervention. Cardio J. 2014;21(3):238–244.
12. Nafae RM, Mohammed MA, Ibrahim DA. Thyroid function in resuscitated patients in the intensive care unit. J Cardiol. 2021;63(2):513–521.
13. Chuang CP, Jong YS, Wu CY, Lo HM. Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure. Am J Cardiol. 2014;113(5):845–850.
14. De Alfiere W, Nistico F, Borgonzi T, et al. Thyroid hormones as predictors of short-and long-term mortality in very old hospitalized patients. J Gerontol - Ser A Biol Sci Med Sci. 2013;68(9):1122–1128.
15. Van Den Bergh E. Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol. 2000;143(1):1–3.
16. Pilkat K, Langgarter J, Buettner R, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism. 2007;56(2):239–244.
17. Adler SM, Wartofsky L. The nonthyroidal illness syndrome. Endocrinol Metab Clin North Am. 2007;36(3):657–672.
18. Fallbacki B, Bogowicz M, Lee S, Beutler B, Grzelka A, et al. Higher free triiodothyronine concentration is associated with lower prevalence of multiorgan complications and better metabolic control in adult euthyroid people with type 1 diabetes. Endocrine. 2018;63(3):485–486.
19. Meyer S, Schultz P, Wieland M, Nusbaum C, Mueller B, Christ-Crain M. Low triiodothyronine syndrome: a prognostic marker for outcome in sepsis? Endocrine. 2011;39(2):167–174.
20. Hochberg I. Insulin detemir use is associated with higher occurrence of hypoglycemia in hospitalized patients with hypoalbddinemia. Diabetes Care. 2018;41(4):e44–e46.
21. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
22. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2017. https://www.R-project.org. Accessed November 11, 2020.
23. Ekenzengi S, Carinelli E, Altun S, et al. Nutritional and prognostic significance of sick euthyroid syndrome in non-small cell lung cancer patients. Intern Med. 2008;47(4):211–216.
24. Lee S, Farwell AP. Euthyroid sick syndrome. Comp Physiol. 2011;6(2):1071–1086.
25. Pang XP, Hershman JM, Chung M, Pekary AE. Characterization of tumor necrosis factor-α receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology. 1989;125(4):1783–1788.
26. Ashizawa K, Yamashita S, Nagayama Y, et al. Interferon-γ inhibits thyrotropin-induced thyroid peroxidase gene expression in cultured human thyrocytes. J Clin Endocrinol Metab. 1989;69(2):475–477.
27. Asakawa H, Hanafusa T, Kobayashi T, Takei S, Kono N, Tarui SE. Interferon-γ reduces the thyroid peroxidase content of cultured human thyrocytes and inhibits its increase induced by thyrotropin. J Clin Endocrinol Metab. 1992;74(6):1331–1335.
28. Sato K, Satoh T, Shizuma K, et al. Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-α, and interferon-γ in human thyrocytes in suspension culture. J Clin Endocrinol Metab. 1990;70(6):1735–1743.
29. Poth M, Tieng YC, Wartofsky L. Inhibition of TSH activation of human cultured thyroid cells by tumor necrosis factor: an explanation for decreased thyroid function in systemic illness? Thyroid. 1991;1(3):235–240.
30. Yamazaki K, Yamada E, Kanaji Y, et al. Interleukin-6 (IL-6) inhibits thyroid function in the presence of soluble IL-6 receptor in cultured human thyroid follicles. Endocrinology. 1996;137(11):4857–4863.
31. Kraiem Z, Sobeil E, Sadeh O, Kinarty A, Lahat N. Effects of γ-interferon on DR antigen expression, growth, 3, 5-triiodothyronine secretion, iodide uptake, and cyclic adenosine 3′, 5′-monophosphate accumulation in...
32. de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal illness syndrome. J Endocrinol. 2015;225(3):R67–R81.
33. Fliers E, Guldenaar SEF, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab. 1997;82(12):4032–4036.
34. Papanicolaou DA. Euthyroid sick syndrome and the role of cytokines. Rev Endocr Metab Disord. 2000;1(1-2):43.
35. Feelders RA, Swaak AJC, Romijn JA, et al. Characteristics of recovery from the euthyroid sick syndrome induced by tumor necrosis factor alpha in cancer patients. Metabolism. 1999;48(3):324–329.
36. Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med. 1979;300(11):579–584.
37. Brent GA, Hershman JM. Thyroxine therapy in patients with severe non-thyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63(1):1–8.
38. Ginoer D. Comment on dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999;84(6):2261–2262.
39. McGonagle D, Sharif K, O’Regan A, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.
40. Ragab D, Salah Eldin H, Taemah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.